Back to Agenda
Session 1: Exploring the New Horizons in Pharmacovigilance - New Things QPPVs Should be Aware Of
Session Chair(s)
Maarten Lagendijk, MSc
Deputy EU QPPV
MSD, Netherlands
Magnus Ysander, MD
EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden
As a QPPV, staying ahead of the rapid scientific and technological advancements in medicine is crucial. Join us for an enlightening session that offers an introductory exploration of two exciting topics shaping the future of pharmacovigilance: New Treatment Modalities and Digital Health Solutions. Gain foundational knowledge of the safety considerations associated with these cutting-edge innovations, understand their potential connections to pharmacovigilance, and discover how they could shape safety monitoring of patients and enhance risk minimization activities.
Speaker(s)
New Modalities Around the Corner: CAR-t, Gene Therapies and More
Suzanne Hansen, PhD, MPharm
Novo Nordisk Inc., Denmark
Safety Surveillance Principal Specialist
Combination Products, Medical Devices (IVDR/MDR)
Christian Jensen
TÜV SÜD Denmark Medical Health Services, Denmark
Product Reviewer
Panel Discussion and Q&A
David John Lewis, PhD
Novartis Pharma Gmbh, Switzerland
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance
Have an account?